Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will be presenting at the BIO CEO & Investor Conference taking place February 16-18. Presentations detail
February 11, 2021
· 2 min read